ArticleFrontiers in pharmacology2017
Article in Frontiers in pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 48 citations in OpenAlex.
- Lectin-glycan interactions: a comprehensive cataloguing of cancer-associated glycans for biorecognition and bio-alteration: a review.Glycoconjugate journal · 2024Review
- Deciphering anoikis resistance and identifying prognostic biomarkers in clear cell renal cell carcinoma epithelial cells.Scientific reports · 2024Article
- Amoxetamide A, a new anoikis inducer, produced by combined-culture of Amycolatopsis sp. and Tsukamurella pulmonis.The Journal of antibiotics · 2024Article
- Anti(angiogenic) food components: can be a major source of bias in the investigation of angiogenesis inhibitors.Annals of translational medicine · 2023Review
- Structural Analysis and Characterization of an Antiproliferative Lectin fromInternational journal of molecular sciences · 2023Article
- EGFR and p38Pharmaceuticals (Basel, Switzerland) · 2023Article
- Genome-wide identification, classification, and characterization of lectin gene superfamily in sweet orange (Citrus sinensis L.).PloS one · 2023Article
- Herbal Medicine, Gut Microbiota, and COVID-19.Frontiers in pharmacology · 2021Review
- Mechanisms for Modulating Anoikis Resistance in Cancer and the Relevance of Metabolic Reprogramming.Frontiers in oncology · 2021Review
- A New Lectin fromBioMed research international · 2021Article
- Guaiazulene Triggers ROS-Induced Apoptosis and Protective Autophagy in Non-small Cell Lung Cancer.Frontiers in pharmacology · 2021Article
- Article
- Silencing MR-1 attenuates atherosclerosis in ApoEThe Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2018Article
- MicroRNA-133b/EGFR axis regulates esophageal squamous cell carcinoma metastases by suppressing anoikis resistance and anchorage-independent growth.Cancer cell international · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lectins are a unique class of carbohydrate binding proteins/glycoproteins, and many of them possess anticancer properties. They can induce cell cycle arrest and apoptosis, inhibit protein synthesis, telomerase activity and angiogenesis in cancer cells. In the present study, we have demonstrated the effect of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.